# EDGAR Filing Document

**Accession Number:** 0001827401
**File Stem:** 0001062993-26-000102
**Filing Date:** 2026-1
**Character Count:** 2805
**Document Hash:** 9227dfd9116ef4ed1b05fed1eae695fc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-26-000102.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001062993-26-000102

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260107

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40997
- **FILM NUMBER:** 26516664

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of <u>**January 2026**</u>

Commission File No.<u>**001-40997**</u>

<u>**BRIGHT MINDS BIOSCIENCES INC.**</u><br>(Translation of registrant's name into English)

---

| | |
|:---|:---|
| &nbsp;&nbsp;**400 N Aberdeen St Suite 900**<br><u>**Chicago, IL 60642**</u><br>(U.S. Corporate headquarters) | &nbsp;&nbsp;**1122 Mainland St #228**<br><u>**Vancouver, BC V6B 5L1**</u><br>(Canadian Corporate headquarters) |

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [ ] **Form 40-F [ X ]**

------

On January 7, 2026, Bright Minds Biosciences Inc. (the "Company"), Piper Sandler & Co. ("Piper Sandler") and Cantor Fitzgerald & Co. ("Cantor") mutually agreed to terminate the Equity Distribution Agreement, dated August 25, 2025, between the Company, Piper Sandler and Cantor, effective January 7, 2026.

**INCORPORATION BY REFERENCE**

The disclosure in this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694) filed on February 5, 2025, and (b) registration statement on Form F-3 (File No. 333-289851) filed on August 26, 2025.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| |
|:---|
| **BRIGHT MINDS BIOSCIENCES INC.** |
| */s/ Ryan Cheung* |
| Ryan Cheung |
| Chief Financial Officer |

---

Date: January 7, 2026

------